Lumexa Imaging Holdings, Inc. LMRI
10.21
0.33
3.34%
as of 25 Sep
- Market cap
- $949.2M
- P/E
- 0.0×
Follow LMRI
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+3 more TTM periods Free account |
— | — | 0.00% | 0.00% | |
| — | 0.00% | (3.51%) | (5.51%) | ||
ROIC |
0.00% | 0.00% | 48.32% | 48.10% | |
Return on Tangible Assets |
— | 0.00% | (28.17%) | (21.30%) | |
Average Days of Receivables |
— | 0.00 | 31.75 | 35.09 | |
Free Cash Flow per Share |
0.14 | (0.10) | (0.24) | 0.16 | |
Free Cash Flow |
10.04 | (7.22) | (22.88) | 14.93 | |
Capital Expenditures |
(56.31) | (53.13) | (31.00) | (39.95) | |
Piotroski F-Score |
— | 0.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 3.04% | 0.53% | 3.52% | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 11.44 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
— | — | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 4.52% | |
Share Based Compensation of Revenue |
— | — | 0.00% | 2.22% | |
Interest Coverage |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | (0.13) | (1.10) | |
Depreciation/Fixed assets |
0.00 | 1.06 | 0.70 | 0.68 | |
Capex/Depreciation |
(0.30) | (0.35) | (0.29) | (0.38) | |
Revenue per Share |
0.00 | 0.00 | 18.46 | 18.66 | |
Operating CF per Share |
0.95 | 0.65 | 0.08 | 0.57 | |
Capex per Share |
(0.81) | (0.75) | (0.32) | (0.42) | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.02 | |
Net Profit Margin |
— | — | (3.40%) | (2.78%) |
Columns are period end dates